Clinical and laboratory features of the CLL patients involved in this study
| CLL patient no. . | % CD38+ . | % ZAP-70+ . | Cytogenetic abnormalities, % cells . | IGHV mutation status* . | Lymph node/spleen/liver enlargement† . | Rai stage at diagnosis and when 2H2O study began . | Status . | Time to first treatment, mo‡ . | Mean WBC (beginning-end of study)§ . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Δ11q22 . | Tri12 . | Δ13q14 . | Δ17p23 . | |||||||||
| 189 | 2 | 7 | < 5 | < 5 | 70 | < 5 | M/UM | +/−/− | 0-IV | Expired | 53 | 107 (76-175) |
| 280 | 1 | 29 | < 5 | < 5 | 99 | < 5 | M | −/+/+ | 0-II | Alive | 108 | 58 (61-75) |
| 321 | 10 | 95 | < 5 | 59 | < 5 | < 5 | UM | −/−/− | 0-0 | Alive | None | 73 (102-90) |
| 332 | 66 | 88 | na | < 5 | 93.5 | < 5 | UM | +/−/− | I-I | Alive | 28 | 74 (na-87) |
| 355 | 25 | 18 | 68 | < 5 | 25 | < 5 | UM | +/−/− | I-I | Expired | 88 | 228 (71-310) |
| 452 | 36 | 48 | na | na | na | na | M/UM | +/−/− | 0-I | Alive | 36 | 79 (63-105) |
| 546 | 7 | 6 | 0 | 0 | 78 | 0 | M | −/−/− | 0-0 | Alive | None | 32 (27-35) |
| 569 | 98 | 40 | 0 | 0 | 0 | 0 | UM | −/+/− | II-II | Alive | None | 73 (52-95) |
| 606 | 8 | 5 | 0 | 0 | 68 | 0 | M | −/−/− | 0-0 | Alive | None | 29 (30-26) |
| 625 | 54 | 57 | 80 | 0 | 0 | 0 | UM | ++/−/− | II-II | Alive | 17 | 297 (245-261) |
| 822 | 22 | 56 | 0 | 0 | na | 0 | UM | −/+/− | 0-III | Alive | 108 | 43 (30-75) |
| 875 | 14 | 18 | 0 | 0 | 0 | 0 | M | −/−/− | 0-0 | Alive | None | 15 (15-15) |
| 931 | 63 | 49 | na | na | na | na | UM | −/−/− | 0-0 | Expired | None | 20 (17-28) |
| CLL patient no. . | % CD38+ . | % ZAP-70+ . | Cytogenetic abnormalities, % cells . | IGHV mutation status* . | Lymph node/spleen/liver enlargement† . | Rai stage at diagnosis and when 2H2O study began . | Status . | Time to first treatment, mo‡ . | Mean WBC (beginning-end of study)§ . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Δ11q22 . | Tri12 . | Δ13q14 . | Δ17p23 . | |||||||||
| 189 | 2 | 7 | < 5 | < 5 | 70 | < 5 | M/UM | +/−/− | 0-IV | Expired | 53 | 107 (76-175) |
| 280 | 1 | 29 | < 5 | < 5 | 99 | < 5 | M | −/+/+ | 0-II | Alive | 108 | 58 (61-75) |
| 321 | 10 | 95 | < 5 | 59 | < 5 | < 5 | UM | −/−/− | 0-0 | Alive | None | 73 (102-90) |
| 332 | 66 | 88 | na | < 5 | 93.5 | < 5 | UM | +/−/− | I-I | Alive | 28 | 74 (na-87) |
| 355 | 25 | 18 | 68 | < 5 | 25 | < 5 | UM | +/−/− | I-I | Expired | 88 | 228 (71-310) |
| 452 | 36 | 48 | na | na | na | na | M/UM | +/−/− | 0-I | Alive | 36 | 79 (63-105) |
| 546 | 7 | 6 | 0 | 0 | 78 | 0 | M | −/−/− | 0-0 | Alive | None | 32 (27-35) |
| 569 | 98 | 40 | 0 | 0 | 0 | 0 | UM | −/+/− | II-II | Alive | None | 73 (52-95) |
| 606 | 8 | 5 | 0 | 0 | 68 | 0 | M | −/−/− | 0-0 | Alive | None | 29 (30-26) |
| 625 | 54 | 57 | 80 | 0 | 0 | 0 | UM | ++/−/− | II-II | Alive | 17 | 297 (245-261) |
| 822 | 22 | 56 | 0 | 0 | na | 0 | UM | −/+/− | 0-III | Alive | 108 | 43 (30-75) |
| 875 | 14 | 18 | 0 | 0 | 0 | 0 | M | −/−/− | 0-0 | Alive | None | 15 (15-15) |
| 931 | 63 | 49 | na | na | na | na | UM | −/−/− | 0-0 | Expired | None | 20 (17-28) |
Note that WBC data for CLL 569 were incomplete (only beginning and end values were available) and WBC count of CLL 332 at the beginning of the study was not available.
na indicates data not available.
Two percent or less difference from the germline gene defines a patient as IGHV unmutated (UM); more than 2% difference defines a patient as IGHV mutated (M).
Lymph nodes: + indicates 1-1.5 cm; ++, 1.5-3 cm. + for spleen and liver defines them as palpable by physical examination or enlarged on imaging (ultrasound or computed tomography scan). Only data 6 months before or after the study are included.
Time from initial diagnosis to first treatment for clinical progression of CLL.
Mean WBC count recorded during 2H2O protocol period; in parentheses are values at the beginning and end of the protocol.